Eficacia Clínica de los Inhibidores Alternativos de TNF y Secukinumab entre no-Respondedor Primario y Secundario a una Therapie Previa con Inhibidor de TNF en Espondilitis Anquilosante
Mod Rheumatol. 2023 doi: 10.1093/mr/roac005
This study demonstrated comparable drug retention between AS patients treated with alternative TNFi and secukinumab after failing to respond to prior TNFi therapy. The objective of this study was to compare the drug retention times and clinical efficacy of alternative TNFi and secukinumab in primary and secondary
non-responders with AS.
This data will influence decision making in respect to changing biologics in patients who fail prior TNFi therapy. In particular, clinicians can base the decision on whether the AS patient is a primary or secondary non-responder.
Keywords:
